News | March 30, 2026
Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Capital infusion to accelerate Earendil’s R&D platform
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The company announced positive topline data from the Phase 3 ADorable-1 trial
The trial will enroll up to 42 patients in Finland across four cohorts
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
